Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Total Revenue of $958.40 million for the year ending 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +432.1% in Total Revenue from 2024 to 2025.
- This data is from MADRIGAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $0.00 | Q3 2019: $0.00 | Q2 2020: $0.00 | Q3 2020: $0.00 | Q1 2021: $0.00 | Q2 2021: $0.00 | Q3 2021: $0.00 | Q1 2022: $0.00 | Q2 2022: $0.00 | Q3 2022: $0.00 | Q4 2022: $0.00 | Q1 2023: $0.00 | Q2 2023: $0.00 | Q2 2023: $0.00 | Q3 2023: $0.00 | Q3 2023: $0.00 | Q4 2023: $0.00 | Q1 2024: $0.00 | Q1 2024: $0.00 | Q2 2024: $14.64 million | Q3 2024: $62.18 million | Q1 2025: $137.25 million | Q2 2025: $212.80 million | Q3 2025: $287.27 million.
- Over the full 10 years of available data (2012 to 2025), MADRIGAL PHARMACEUTICALS, INC.'s Total Revenue has grown by 651,874.8%.
- Historical annual values: Fiscal year 2025: $958.40 million | Fiscal year 2024: $180.13 million | Fiscal year 2023: $0.00 | Fiscal year 2023: $0.00 | Fiscal year 2022: $0.00 | Fiscal year 2022: $0.00 | Fiscal year 2021: $0.00 | Fiscal year 2020: $0.00 | Fiscal year 2019: $0.00 | Fiscal year 2012: $147.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: